US03969K1088 - Common Stock
ARCUTIS BIOTHERAPEUTICS INC
NASDAQ:ARQT (4/24/2024, 7:00:01 PM)
After market: 8.76 +0.01 (+0.11%)8.75
+0.01 (+0.11%)
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 268 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE is a once-daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an established biological target in dermatology. The company is also developing roflumilast cream for the treatment of atopic dermatitis. ZORYVE is designed for simple once-a-day application for chronic use, does not burn or sting on application, and can be used on any part of the body, including sensitive or difficult-to-treat areas, such as the face and intertriginous regions.
ARCUTIS BIOTHERAPEUTICS INC
3027 Townsgate Road, Suite 300
Westlake Village CALIFORNIA 91361
P: 18054185006
CEO: Todd Franklin Watanabe
Employees: 268
Website: https://arcutis.com/
Industry veteran with over 40 years of experience in finance, investment management, and investment banking
Arcutis today announced that David Topper has been appointed Chief Financial Officer effective April 10, 2024....
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
Here you can normally see the latest stock twits on ARQT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: